INMUNE BIO INC. - COMMON STOCK

INmune Bio, Inc. to Provide Additional Manufacturing Information to FDA as Part of IND Application for XPro1595™ in Alzheimer’s Disease

23 May 2022 16:00:00 By Nasdaq GlobeNewswire

INmune Bio, Inc. to Present at the H.C. Wainwright Global Hybrid Investment Conference on May 24th

18 May 2022 09:00:02 By Nasdaq GlobeNewswire

INmune Bio, Inc. Presents Data Demonstrating XPro™ Promotes Remyelination in Gray Matter at 3rd European Conference on Neuroinflammation

10 May 2022 08:00:01 By Nasdaq GlobeNewswire

INmune Bio, Inc. Announces First Quarter 2022 Results and Provides Business Update

05 May 2022 16:00:00 By Nasdaq GlobeNewswire

INmune Bio, Inc. to Report First Quarter 2022 Financial Results and Provide a Corporate Update on Thursday, May 5

28 Apr 2022 07:00:02 By Nasdaq GlobeNewswire

INmune Bio, Inc. to Participate at the B. Riley Neuro & Ophthalmology Conference

25 Apr 2022 16:00:00 By Nasdaq GlobeNewswire

INmune Bio Announces First Patient Dosed in Phase 2 XPro1595 Trial for Treatment of Neuroinflammation as a Cause of Alzheimer’s disease

13 Apr 2022 16:00:00 By Nasdaq GlobeNewswire

INmune Bio, Inc. to Present Preclinical Data on INB03 at the American Association for Cancer Research (AACR) Annual Meeting 2022

11 Apr 2022 08:00:01 By Nasdaq GlobeNewswire

INmune Bio, Inc. Highlights INKmune™ Data Featured in NK Cells in Solid Tumors Workshop at Innate Killer Summit

04 Apr 2022 09:00:02 By Nasdaq GlobeNewswire

INmune Bio, Inc. Announces Company’s CSO Dr. Mark Lowdell to Co-Host the “NK Cells in Solid Tumors” Workshop at Innate Killer Summit

30 Mar 2022 08:00:00 By Nasdaq GlobeNewswire

INmune Bio, Inc. Spotlights Key Findings in Presentations at AD/PD™ 2022

25 Mar 2022 09:00:00 By Nasdaq GlobeNewswire

INmune Bio, Inc. Announces Nine Data Presentations at AD/PD™ 2022 - International Conference on Alzheimer's and Parkinson's Diseases

15 Mar 2022 08:00:01 By Nasdaq GlobeNewswire

INmune Bio, Inc. to Participate in the 32nd Annual Oppenheimer Healthcare Conference and the 2022 Maxim Group Virtual Growth Conference

14 Mar 2022 16:30:00 By Nasdaq GlobeNewswire

INmune Bio, Inc. Announces Fourth Quarter and Full Year 2021 Results and Provides Business Update

03 Mar 2022 16:00:00 By Nasdaq GlobeNewswire

INmune Bio, Inc. to Report Fourth Quarter 2021 Financial Results and Provide a Corporate Update on Thursday, March 3

23 Feb 2022 09:00:02 By Nasdaq GlobeNewswire

INmune Bio, Inc. to Present at the BIO CEO & Investor Conference

08 Feb 2022 09:00:02 By Nasdaq GlobeNewswire

INmune Bio, Inc. Announces Research Collaboration with Chinese University of Hong Kong to Evaluate INKmune in Nasopharyngeal Cancer

25 Jan 2022 09:00:03 By Nasdaq GlobeNewswire

INmune Bio, Inc. to Participate in January Investor Conferences and a Medical Meeting

04 Jan 2022 09:00:01 By Nasdaq GlobeNewswire

INmune Bio, Inc. Announces Key Breast Cancer Treatment Resistance Data to be Presented at the 2021 San Antonio Breast Cancer Symposium

09 Dec 2021 09:01:03 By Nasdaq GlobeNewswire

INmune Bio, Inc. Announces Two Presentations at the 2021 British Society of Immunology Congress and Provides 119-day data on First patient in MDS trial.

01 Dec 2021 09:00:01 By Nasdaq GlobeNewswire